Soligenix’s RiVax Receives the US FDA’s Fast Track Designation for the Prevention of Ricin Poisoning

 Soligenix’s RiVax Receives the US FDA’s Fast Track Designation for the Prevention of Ricin Poisoning

Soligenix’s RiVax Receives the US FDA’s Fast Track Designation for the Prevention of Ricin Poisoning

Shots:

  • The US FDA has granted FT designation to RiVax (heat stable ricin toxin vaccine) to prevent ricin intoxication. Soligenix will submit BLA for the vaccine on a rolling basis, letting the FDA review sections of the BLA prior to receiving the complete submission
  • FDA’s FT designation is intended to facilitate the development and expedite the review of new drugs and biologics and is granted to the therapy
  • RiVax is Soligenix’s heat-stable recombinant subunit vaccine, developed to prevent exposure to ricin toxin, comprising of the genetically altered version of a Ricin Toxin A (RTA) chain containing two mutations that inactivate the toxicity of the ricin molecule

Click here ­to­ read full press release/ article | Ref: PRNewswire | Image: American Pharmacy News

Tuba Khan

Tuba Khan is Senior Editor at PharmaShots. She is curious, creative, and passionate about recent updates and innovation in the Life sciences industry. She covers Biopharma, MedTech, and Digital health segments. Tuba also has an experience of digital and social media marketing and runs the campaigns independently. She can be contacted on tuba@pharmashots.com

Related post